Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).
2016
10018Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major problem after oxaliplatin treatment. Calmangafodipir (CaM) has shown promising activities in model systems in preventin...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI